Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from Piper Jaffray Companies

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating reissued by equities researchers at Piper Jaffray Companies in a report released on Sunday, January 7th. They presently have a $182.00 price target on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price objective suggests a potential upside of 41.01% from the stock’s previous close.

Several other research firms have also recently issued reports on ALNY. Morgan Stanley boosted their target price on Alnylam Pharmaceuticals from $101.00 to $130.00 and gave the company an “equal weight” rating in a research note on Thursday, November 9th. Cowen reaffirmed a “buy” rating and issued a $151.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, November 9th. Credit Suisse Group upped their price target on Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the stock an “outperform” rating in a research note on Friday, November 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $152.00 price target (up from $125.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, November 3rd. Finally, JPMorgan Chase & Co. raised Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Thursday, November 9th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $121.20.

Alnylam Pharmaceuticals (ALNY) opened at $129.07 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83. Alnylam Pharmaceuticals has a 12 month low of $35.98 and a 12 month high of $147.63. The stock has a market capitalization of $12,691.56, a P/E ratio of -24.58 and a beta of 2.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The business had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $28.15 million. During the same period last year, the firm posted ($1.21) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 24.8% on a year-over-year basis. sell-side analysts anticipate that Alnylam Pharmaceuticals will post -5.28 EPS for the current fiscal year.

In other news, SVP Laurie Keating sold 6,249 shares of the company’s stock in a transaction on Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total transaction of $757,378.80. Following the transaction, the senior vice president now directly owns 17,749 shares of the company’s stock, valued at $2,151,178.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Michael Mason sold 36,745 shares of the company’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $131.59, for a total value of $4,835,274.55. Following the transaction, the vice president now directly owns 6,352 shares in the company, valued at $835,859.68. The disclosure for this sale can be found here. Insiders sold 274,075 shares of company stock worth $35,356,089 over the last three months. Corporate insiders own 4.30% of the company’s stock.

Several large investors have recently made changes to their positions in ALNY. Schwab Charles Investment Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 33.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 243,415 shares of the biopharmaceutical company’s stock valued at $19,415,000 after purchasing an additional 60,906 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Alnylam Pharmaceuticals by 9.2% during the second quarter. Bank of New York Mellon Corp now owns 333,942 shares of the biopharmaceutical company’s stock valued at $26,634,000 after purchasing an additional 28,260 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Alnylam Pharmaceuticals by 12.7% during the second quarter. Legal & General Group Plc now owns 27,883 shares of the biopharmaceutical company’s stock valued at $2,224,000 after purchasing an additional 3,144 shares in the last quarter. Prudential Financial Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 4.8% during the second quarter. Prudential Financial Inc. now owns 4,404 shares of the biopharmaceutical company’s stock valued at $351,000 after purchasing an additional 200 shares in the last quarter. Finally, Neuberger Berman Group LLC bought a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at $229,000. 88.39% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by BBNS and is the property of of BBNS. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://baseballnewssource.com/markets/piper-jaffray-companies-reiterates-buy-rating-for-alnylam-pharmaceuticals-alny/1819526.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.